{
    "nct_id": "NCT03164603",
    "official_title": "A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors",
    "inclusion_criteria": "* Histologically or cytologically confirmed solid tumor cancer (including glioblastoma)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematologic and organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active or history of medically significant autoimmune disease\n* Cytotoxic therapy or investigational agent use within 28 days\n* Human immunodeficiency virus (HIV), active hepatitis B or C\n* Untreated brain metastases\n* Known QT interval prolongation\n* Use of concomitant medications with high risk of causing Torsades des Pointes.\n* Use of immune suppressive agents within 30 days\n* More than one active malignancy at the time of enrollment",
    "miscellaneous_criteria": ""
}